GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

47.03 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2 3 4 5 6 7 8 9

...

45 46 Next >

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma ↗

July 08, 2025

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Via Stocktwits

CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel ↗

July 02, 2025

The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations.

Via Stocktwits

Topics Government

Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons ↗

July 02, 2025

Via Benzinga

Price Over Earnings Overview: GSK ↗

July 02, 2025

Via Benzinga

Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election ↗

June 30, 2025

The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election.

Via Stocktwits

Topics Government Law Enforcement

GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses ↗

June 27, 2025

Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.

Via Benzinga

Why This Looming Supreme Court Decision Could Rattle Gilead Sciences ↗

June 27, 2025

The U.S. Supreme Court could make a decision Friday that would rattly Gilead Sciences' newest HIV prevention drug.

Via Investor's Business Daily

FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis

June 24, 2025

From GSK plc

Via Business Wire

AppLovin, First Solar And Li Auto Are Among Top 10 Large Cap Losers Last Week (June 16-20): Are The Others In Your Portfolio? ↗

June 22, 2025

Top 10 worst performing large-cap stocks last week: APP, FSLR, JHX, ONC, GSK, ACN, ANET, LI, CPAY, MA. Reasons include short-sell report, tax bill, and market selloff.

Via Benzinga

How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗

June 20, 2025

The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.

Via Investor's Business Daily

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag ↗

June 20, 2025

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

Via Benzinga

GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US

June 16, 2025

From GSK plc

Via Business Wire

GSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail Optimism ↗

June 13, 2025

The company is looking forward to a decision from the regulator on the application in the first half of 2026.

Via Stocktwits

FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up ↗

June 13, 2025

The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.

Via Benzinga

Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines? ↗

June 10, 2025

Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."

Via Stocktwits

Topics Government

Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. ↗

June 09, 2025

A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.

Via Investor's Business Daily

Topics Government

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 09, 2025

Via Benzinga

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps ↗

June 04, 2025

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Via Benzinga

Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? ↗

June 02, 2025

Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a favorable safety profile.

Via Benzinga

Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data ↗

May 30, 2025

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.

Via Benzinga

Small-Cap Movers Under $1: HIT, SPRO, SGN, PRSO, SGBX Drive Momentum Across AI, Biotech, Crypto, Software, Etc.

May 28, 2025

Via AB Newswire

Topics Artificial Intelligence

iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’ ↗

May 28, 2025

The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended.

Via Stocktwits

Topics Intellectual Property

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? ↗

May 28, 2025

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.

Via Benzinga

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled ↗

May 28, 2025

The early stop follows the trial meeting its primary endpoint of non-inferiority of Tebipenem HBr compared to an intravenous medicine in hospitalised adult patients with cUTI.

Via Stocktwits

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

May 22, 2025

From GSK plc

Via Business Wire

GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion ↗

May 14, 2025

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

Via Benzinga

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile ↗

May 13, 2025

iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value.

Via Benzinga

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

May 09, 2025

From GSK plc

Via Business Wire

Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales ↗

April 30, 2025

GSK beat Q1 estimates with $9.46 billion in sales and $1.13 EPS, driven by strong Specialty Medicines and meningitis vaccine performance.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.